You have 9 free searches left this month | for more free features.

Overall Status

Recruiting (11)

Completed (6)

Not yet recruiting (4)

Active, not recruiting (3)

Enrolling by invitation (2)

Unknown status (1)

Sign in for free

Phase

phase 2 (15)

phase 1 (6)

phase 1/phase 2 (2)

phase 3 (2)

early phase 1 (1)

phase 2/phase 3 (1)

Collaborator

Mirati Therapeutics Inc. (5)

BeiGene (2)

AstraZeneca (1)

Cancer Research UK (1)

Experimental Cancer Medicine Centres (1)

National Cancer Institute (NCI) (1)

Pfizer (1)

Study Documents

Trial Website (1)

Intervention Type

drug (27)

biological (3)

other (2)

Funder Type

Industry (14)

Other (13)

Study Type

Interventional (27)

sitravatinib

Showing 26 - 27 of 27

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

NSCLC (NSCLC) Trial in Worldwide (Tislelizumab, Docetaxel, Sitravatinib)

Recruiting

Non-Small Cell Lung Cancer (NSCLC)

Tislelizumab
+2 more

Tucson, Arizona
+112 more

Nov 9, 2022

NSCLC, Carcinoma, Squamous Cell, Adenocarcinoma Trial in United Kingdom (AZD4547, Vistusertib, Palbociclib)

Active, not recruiting

Non-Small Cell Lung Cancer
+2 more

AZD4547
+10 more

Aberdeen, United Kingdom
+24 more

Nov 2, 2021